Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma

A. N. Krutchik, A. U. Buzdar, G. R. Blumenschein, J. G. Sinkovics

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of tericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.

Original languageEnglish (US)
Pages (from-to)1565-1567
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number10
StatePublished - Dec 1 1978
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma'. Together they form a unique fingerprint.

Cite this